UNSPSC 51112030: Abemaciclib

Abemaciclib is a drug for the treatment of advanced or metastatic breast cancers.

UNSPSC 51112030 Abemaciclib, a Commodity code, does not appear in recent state and local government procurement activity. The source contains no solicitations for abemaciclib or any other branded cancer therapeutics; the single recent opportunity tagged under this code—a Seminole County, Florida IFB for naloxone and safe drug deactivation systems—is unrelated to the code's scope and reflects a tagging mismatch rather than legitimate procurement of abemaciclib products.

State and local governments show minimal to no current demand for this specific pharmaceutical. Abemaciclib is a prescription oncology medication (a CDK4/6 inhibitor) typically managed through centralized pharmaceutical contracting at the state level or through health plan formulary agreements rather than local purchasing. The recent opportunities block shows no evidence of abemaciclib procurement from any issuing body—state health departments, counties, municipalities, school districts, transit authorities, or special districts. Broader UNSPSC pharmaceutical codes (such as generic multi-source pharmaceuticals and OTC products through MMCAP, or naloxone procurement at the county level) reflect active state and local spend, but branded prescription oncology agents appear outside the typical scope of published state and local RFP activity. Any abemaciclib opportunity would likely be embedded in statewide health plan procurement, Medicaid pharmacy-benefit contracts, or hospital-system acquisitions, channels that do not surface in standard state and local solicitation databases. No representative opportunities, issuing-body mix, or geographic concentration are supported by the source.